-
Je něco špatně v tomto záznamu ?
In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048
M. Pohanka, D. Jun, K. Kuca,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Taylor & Francis Open Access
od 2002-01-01
Medline Complete (EBSCOhost)
od 2007-02-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- acetylcholinesterasa metabolismus MeSH
- Alzheimerova nemoc farmakoterapie enzymologie patologie MeSH
- butyrylcholinesterasa metabolismus MeSH
- cholinesterasové inhibitory chemie farmakologie terapeutické užití MeSH
- lidé MeSH
- obidoxim chlorid farmakologie MeSH
- oximy farmakologie MeSH
- pralidoximové sloučeniny farmakologie MeSH
- pyridinové sloučeniny farmakologie MeSH
- reaktivátory cholinesterasy chemie farmakologie terapeutické užití MeSH
- trichlorfon chemie farmakologie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Trichlorfon is a specific inhibitor of cholinesterases. It was typically used as an insecticide; however, trichlorfon was described as useful for symptomatic treatment of Alzheimer's disease some years ago. The presented study is aimed at reactivation of trichlorfon-inhibited butyrylcholinesterase since this enzyme play an important role in Alzheimer's disease as deputy for acetylcholinesterase and furthermore it could be applied as a scavenger in case of overdosing. We used in vitro reactivation test for considering only reactivation efficacy of butyrylcholinesterase that is inhibited by trichlorfon and not reactivation of butyrylcholinesterase inhibited by trichlorfon metabolic products. Four reactivators were used: HI-6, pralidoxime, obidoxime, and K048. Although all of the reactivators seem to be effective at 1 mM concentration, a lower concentration was not able ensure sufficient reactivation. There was also an observed lowering of reactivation efficacy when butyrylcholinesterase was exposed to trichlorfon for a longer time interval.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026524
- 003
- CZ-PrNML
- 005
- 20121207114828.0
- 007
- ta
- 008
- 120817s2009 enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1080/14756360802328315 $2 doi
- 035 __
- $a (PubMed)18825528
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pohanka, Miroslav $u Faculty of Military Health Sciences, Center of Advanced Studies, University of Defence, Hradec Kralove, Czech Republic.
- 245 10
- $a In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048 / $c M. Pohanka, D. Jun, K. Kuca,
- 520 9_
- $a Trichlorfon is a specific inhibitor of cholinesterases. It was typically used as an insecticide; however, trichlorfon was described as useful for symptomatic treatment of Alzheimer's disease some years ago. The presented study is aimed at reactivation of trichlorfon-inhibited butyrylcholinesterase since this enzyme play an important role in Alzheimer's disease as deputy for acetylcholinesterase and furthermore it could be applied as a scavenger in case of overdosing. We used in vitro reactivation test for considering only reactivation efficacy of butyrylcholinesterase that is inhibited by trichlorfon and not reactivation of butyrylcholinesterase inhibited by trichlorfon metabolic products. Four reactivators were used: HI-6, pralidoxime, obidoxime, and K048. Although all of the reactivators seem to be effective at 1 mM concentration, a lower concentration was not able ensure sufficient reactivation. There was also an observed lowering of reactivation efficacy when butyrylcholinesterase was exposed to trichlorfon for a longer time interval.
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a Alzheimerova nemoc $x farmakoterapie $x enzymologie $x patologie $7 D000544
- 650 _2
- $a butyrylcholinesterasa $x metabolismus $7 D002091
- 650 _2
- $a cholinesterasové inhibitory $x chemie $x farmakologie $x terapeutické užití $7 D002800
- 650 _2
- $a reaktivátory cholinesterasy $x chemie $x farmakologie $x terapeutické užití $7 D002801
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a obidoxim chlorid $x farmakologie $7 D009768
- 650 _2
- $a oximy $x farmakologie $7 D010091
- 650 _2
- $a pralidoximové sloučeniny $x farmakologie $7 D011220
- 650 _2
- $a pyridinové sloučeniny $x farmakologie $7 D011726
- 650 _2
- $a trichlorfon $x chemie $x farmakologie $x terapeutické užití $7 D014236
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jun, Daniel
- 700 1_
- $a Kuca, Kamil
- 773 0_
- $w MED00008009 $t Journal of enzyme inhibition and medicinal chemistry $x 1475-6374 $g Roč. 24, č. 3 (2009), s. 680-3
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/18825528 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207114902 $b ABA008
- 999 __
- $a ok $b bmc $g 948566 $s 783870
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2009 $b 24 $c 3 $d 680-3 $i 1475-6374 $m Journal of enzyme inhibition and medicinal chemistry $n J Enzyme Inhib Med Chem $x MED00008009
- LZP __
- $a Pubmed-20120817/10/04